BR9915025A - Reversão de choque sistêmico induzido por vìrus e insuficiência respiratória por bloqueio da via linfotoxina-beta - Google Patents

Reversão de choque sistêmico induzido por vìrus e insuficiência respiratória por bloqueio da via linfotoxina-beta

Info

Publication number
BR9915025A
BR9915025A BR9915025-5A BR9915025A BR9915025A BR 9915025 A BR9915025 A BR 9915025A BR 9915025 A BR9915025 A BR 9915025A BR 9915025 A BR9915025 A BR 9915025A
Authority
BR
Brazil
Prior art keywords
lymphotoxin
blockade
reversal
viruses
respiratory failure
Prior art date
Application number
BR9915025-5A
Other languages
English (en)
Inventor
Jeff Browning
Maryann Puglielli
Rafi Ahmed
Original Assignee
Biogen Inc
Univ Emory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc, Univ Emory filed Critical Biogen Inc
Publication of BR9915025A publication Critical patent/BR9915025A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C07K16/242—Lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Patente de Invenção: <B>"REVERSãO DE CHOQUE SISTêMICO INDUZIDO POR VìRUS E INSUFICIêNCIA RESPIRATóRIA POR BLOQUEIO DA VIA LINFOTOXINA-BETA"<D>. A invenção refere-se a processos para induzir uma resposta antiviral em um indivíduo, compreendendo administrar ao indivíduo uma quantidade eficaz de um agente de bloqueio de LT-B e um veículo farmaceuticamente aceitável. Em particular, esta invenção provê processos para tratar choque sistêmico induzido por vírus e insuficiência respiratória.
BR9915025-5A 1998-10-09 1999-10-08 Reversão de choque sistêmico induzido por vìrus e insuficiência respiratória por bloqueio da via linfotoxina-beta BR9915025A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10366298P 1998-10-09 1998-10-09
PCT/US1999/023477 WO2000021558A1 (en) 1998-10-09 1999-10-08 Reversal of viral-induced systemic shock and respiratory distress by blockade of the lymphotoxin beta pathway

Publications (1)

Publication Number Publication Date
BR9915025A true BR9915025A (pt) 2001-08-14

Family

ID=22296372

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9915025-5A BR9915025A (pt) 1998-10-09 1999-10-08 Reversão de choque sistêmico induzido por vìrus e insuficiência respiratória por bloqueio da via linfotoxina-beta

Country Status (27)

Country Link
US (3) US20020001585A1 (pt)
EP (1) EP1119370B1 (pt)
JP (2) JP4713738B2 (pt)
KR (1) KR100888832B1 (pt)
CN (1) CN1200733C (pt)
AT (1) ATE329618T1 (pt)
AU (1) AU777492C (pt)
BR (1) BR9915025A (pt)
CA (1) CA2344049C (pt)
CY (1) CY1105059T1 (pt)
CZ (1) CZ20011272A3 (pt)
DE (1) DE69931944T2 (pt)
DK (1) DK1119370T3 (pt)
EA (1) EA006703B1 (pt)
EE (1) EE04661B1 (pt)
ES (1) ES2267294T3 (pt)
HU (1) HUP0103773A3 (pt)
IL (2) IL142284A0 (pt)
IS (1) IS2514B (pt)
NO (1) NO326905B1 (pt)
NZ (1) NZ510560A (pt)
PL (1) PL195264B1 (pt)
PT (1) PT1119370E (pt)
SG (1) SG121778A1 (pt)
SK (1) SK4662001A3 (pt)
TR (1) TR200100974T2 (pt)
WO (1) WO2000021558A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5925351A (en) * 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
US7118742B2 (en) 1997-07-07 2006-10-10 La Jolla Institute For Allergy And Immunology Ligand for herpes simplex virus entry mediator and methods of use
US6998108B1 (en) 1997-07-07 2006-02-14 La Jolla Institute For Allergy And Immunology Antibodies to p30 polypeptides and methods making and using same
US7060667B1 (en) 1998-01-30 2006-06-13 Biogen Idec Ma, Inc. Treatment of follicular lymphomas using inhibitors of the LT pathway
AU777492C (en) * 1998-10-09 2005-05-26 Biogen Ma Inc. Reversal of viral-induced systemic shock and respiratory distress by blockade of the lymphotoxin beta pathway
TR200504220T2 (tr) 1998-12-17 2007-04-24 Biogen Idec Ma Inc. Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem.
WO2001079496A2 (en) * 2000-03-13 2001-10-25 La Jolla Institute For Allergy And Immunology Ligand for herpes simplex virus entry mediator and methods of use
DE60143231D1 (de) * 2000-04-12 2010-11-18 Jolla Inst Allergy Immunolog Ligand des zelleintritt-vermittelnden Proteins von Herpes Simplex und Methoden zu dessen Verwendungen
US20050163782A1 (en) * 2003-06-27 2005-07-28 Biogen Idec Ma Inc. Modified binding molecules comprising connecting peptides
WO2005092927A1 (en) * 2004-03-23 2005-10-06 Biogen Idec Ma Inc. Receptor coupling agents and therapeutic uses thereof
WO2006074399A2 (en) * 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
EP2073833A2 (en) 2006-10-20 2009-07-01 Biogen Idec MA Inc. Treatment of demyelinating disorders with soluble lymphotoxin-beta-receptor
US8338376B2 (en) * 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
EP3750554A3 (en) * 2007-09-18 2021-07-28 La Jolla Institute for Allergy and Immunology Light inhibitors for asthma, lung and airway inflammation, respiratory, interstitial, pulmonary and fibrotic disease treatment
CN106591446A (zh) * 2016-12-07 2017-04-26 中国人民解放军军事医学科学院微生物流行病研究所 细胞通路调控分子在作为药物靶点及诊断ebov感染中的应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4485045A (en) * 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) * 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5795964A (en) * 1990-06-27 1998-08-18 Biogen, Inc. Lymphotoxin-beta and lymphotoxin-beta complexes
CA2086264C (en) 1990-06-27 2002-12-24 Jeffrey L. Browning Surface complexed lymphotoxin
US7030080B2 (en) * 1990-06-27 2006-04-18 Biogen, Inc. Lymphotoxin-β, lymphotoxin-β complexes, pharmaceutical preparations and therapeutic uses thereof
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
DE69334224D1 (de) 1992-12-04 2008-07-17 Biogen Idec Inc Lymphotoxin-beta, lymphotoxin-beta komplexe, pharmazeutische zubereitungen und therapeutische verwendungen davon
EP1407781A1 (en) 1995-01-26 2004-04-14 Biogen, Inc. Anti-lymphotoxin-beta receptor antibodies as anti-tumor agents
US6312691B1 (en) * 1996-01-26 2001-11-06 Jeffrey L. Browning Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents
US5925351A (en) * 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
US6291207B1 (en) * 1995-07-28 2001-09-18 Northwestern University Herpes virus entry receptor protein
US7255854B1 (en) * 1996-10-25 2007-08-14 Biogen, Inc. Use of lymphotoxin-β receptor blocking agents for the treatment of antibody mediated immunological diseases
TR199901636T2 (xx) * 1996-10-25 1999-09-21 Biogen, Inc. �mm�nolojik hastal�klar�n tedavisi i�in terap�tik maddeler olarak ��z�n�r lenfotoksin-beta resept�rleri, anti-lenfotoksin resept�r� antikorlar� ve anti-lenfotoksin ba�� antikorlar�.
GB9622660D0 (en) * 1996-10-31 1997-01-08 Biocine Spa Immunogenic detoxified mutant toxin
US7060667B1 (en) * 1998-01-30 2006-06-13 Biogen Idec Ma, Inc. Treatment of follicular lymphomas using inhibitors of the LT pathway
AU777492C (en) * 1998-10-09 2005-05-26 Biogen Ma Inc. Reversal of viral-induced systemic shock and respiratory distress by blockade of the lymphotoxin beta pathway
TR200504220T2 (tr) * 1998-12-17 2007-04-24 Biogen Idec Ma Inc. Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem.
EP1539793A4 (en) * 2002-07-01 2006-02-01 HUMANIZED ANTIBODIES AGAINST THE RECEPTOR OF LYMPHOTOXIN BETA

Also Published As

Publication number Publication date
CN1200733C (zh) 2005-05-11
CN1323223A (zh) 2001-11-21
EP1119370B1 (en) 2006-06-14
WO2000021558A9 (en) 2001-05-25
HUP0103773A2 (hu) 2002-01-28
HUP0103773A3 (en) 2003-10-28
AU6296499A (en) 2000-05-01
TR200100974T2 (tr) 2001-11-21
CZ20011272A3 (cs) 2001-09-12
SG121778A1 (en) 2006-05-26
AU777492B2 (en) 2004-10-21
DE69931944T2 (de) 2007-02-08
NZ510560A (en) 2003-09-26
PL347177A1 (en) 2002-03-25
WO2000021558A1 (en) 2000-04-20
AU777492C (en) 2005-05-26
ATE329618T1 (de) 2006-07-15
IS5882A (is) 2001-03-09
PT1119370E (pt) 2006-09-29
CA2344049A1 (en) 2000-04-20
NO20011757D0 (no) 2001-04-06
DE69931944D1 (de) 2006-07-27
EE200100211A (et) 2002-08-15
NO326905B1 (no) 2009-03-16
KR20010080073A (ko) 2001-08-22
SK4662001A3 (en) 2001-11-06
EA200100430A1 (ru) 2001-10-22
KR100888832B1 (ko) 2009-03-17
ES2267294T3 (es) 2007-03-01
IL142284A (en) 2009-11-18
EP1119370A1 (en) 2001-08-01
US7452530B2 (en) 2008-11-18
US20090087403A1 (en) 2009-04-02
JP2010155852A (ja) 2010-07-15
EE04661B1 (et) 2006-08-15
DK1119370T3 (da) 2006-10-02
JP2002527403A (ja) 2002-08-27
EA006703B1 (ru) 2006-02-24
US20040198635A1 (en) 2004-10-07
CA2344049C (en) 2009-12-15
IL142284A0 (en) 2002-03-10
PL195264B1 (pl) 2007-08-31
NO20011757L (no) 2001-06-08
US20020001585A1 (en) 2002-01-03
JP4713738B2 (ja) 2011-06-29
CY1105059T1 (el) 2010-03-03
IS2514B (is) 2009-06-15

Similar Documents

Publication Publication Date Title
BR9915025A (pt) Reversão de choque sistêmico induzido por vìrus e insuficiência respiratória por bloqueio da via linfotoxina-beta
YU7296A (sh) Farmaceutska kompozicija koja sadrži kombinaciju jedne protivvirusne supstance i jednog protivzapaljenskog glukokortikoida
TR200002855T2 (tr) Raloksifenin solunum yolu ile veya burundan uygulanması.
BR9913945A (pt) Composição farmacêutica para o tratamento de distúrbios agudos por meio de administração sublingual, e, processo para o tratamento de distúrbios agudos
ID27787A (id) Senyawa, komposisi dan metode untuk pengobatan atau pencegahan infeksi yang disebabkan oleh virus dan penyakit-penyakit yang berkaitan
TR199903053T2 (xx) Benzimidazol t�revleri.
BR9913319A (pt) Composições e métodos para tratamento de doenças mitocondriais
BR9914251A (pt) Formulações orais de liberação sustentada
UY26724A1 (es) Métodos y composiciones para tratar el virus de la hepatitis c
TR200002739T2 (tr) Üst solunum problemlerinin tedavisinde ksilitol kompozisyonları
BR0109779A (pt) Soluções moleculares hidrofìlicas dispersas de carvedilol
BR9911666A (pt) Combinação farmacêutica, uso da combinação, processo para tratamento de uma doença inflamatória em uma pessoa sofrendo de ou susceptìvel a tal doença, e, composição farmacêutica
BR9812753A (pt) Combinação farmacêutica, uso da mesma, processo para tratamento de uma doença inflamatória, e, composição farmacêutica
BR0014003A (pt) Tratamento de combinação com compostos de diaril sufonil uréia e il-1ra
IL101056A (en) Composition for nasal treatment
ATE272628T1 (de) Substituierte gamma-phenyl-delta-lactone und deren analoge, und ihre verwendungen
BR9809951A (pt) Método para tratamento da obesidade
BR9812660A (pt) Composições e métodos para tratar distúrbios respiratórios
EE04493B1 (et) Tsüklopenteeni derivaadid, neid sisaldav farmatseutiline kompositsioon ning ühendite kasutamine ravimina inimestel esinevate motiliini retseptoriga seotud häirete raviks
BR0310061A (pt) Métodos para o tratamento de doenças e condições respiratórias com um inibidor seletivo da inos e um inibidor da pde e suas composições
AP9801286A0 (en) Therapeutic compounds.
BR0212989A (pt) Métodos para tratamento neuroprotetor usando inibidores de inos seletivos
BR0017329A (pt) Formulção farmacêutica de um medicamento, uso de melatonina na fabricação de um medicamento, e, método para prevenção ou tratamento de sintomas de discinesia tardia em um paciente usanto tal medicamento
BRPI0410374A (pt) composição farmacêutica que compreende valsartano
BR9916043A (pt) Composto, uso do mesmo e de seus saisfarmaceuticamente aceitáveis, e, composiçãofarmacêutica para tratamento de infecções deherpes viral em pacientes

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: EMORY UNIVERSITY (US) , BIOGEN IDEC MA, INC. (US)

Free format text: ALTERADO DE: BIOGEN, INC.

B25D Requested change of name of applicant approved

Owner name: EMORY UNIVERSITY (US) , BIOGEN IDEC MA INC. (US)

Free format text: ALTERADO DE: BIOGEN IDEC MA, INC.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 10 (VIII) DA LPI.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.